

VOLUME 40 / SUPPLEMENT 56 / SEPTEMBER 2012

EUROPEAN RESPIRATORY *journal*

OFFICIAL SCIENTIFIC JOURNAL OF THE ERS

Abstracts / *22nd Annual Congress*

Vienna, Austria 1–5 September 2012



ERS

EUROPEAN
RESPIRATORY
SOCIETY

every breath counts

EUROPEAN RESPIRATORY journal

Impact factor:
5.895

CHIEF EDITORS

Anh Tuan Dinh-Xuan
Dept of Cardiorespiratory
Medicine,
Cochin Hospital,
University Paris Descartes,
27, rue du faubourg
Saint-Jacques,
75014 Paris,
France
Tel: 33 158412341
Fax: 33 158412345
E-mail: erj.chief-editors@ersnet.org

Vito Brusasco
Dept of Internal Medicine,
Medical School,
University of Genoa,
viale Benedetto XV, 6,
16132 Genoa,
Italy
Tel: 39 0103537690
Fax: 39 0103537690
E-mail: erj.chief-editors@ersnet.org

ASSISTANT TO THE CHIEF EDITORS

Sy Duong-Quy
Tel: 33 158411942 Fax: 33 158412345
E-mail: sy.duong-quy@cch.aphp.fr

PUBLICATIONS OFFICE

Managing Editor: **Neil Bullen**
442 Glossop Road, Sheffield,
S10 2PX, UK
Tel: +44 114 267 2860 Fax: +44 114 266 5064
E-mail: neil.bullen@ersj.org.uk

ASSOCIATE EDITORS

N. Ambrosino
Pisa, Italy

I. Annesi-Maesano
Paris, France

J.L. Black
Sydney, Australia

P. Chané
Marseille, France

V. Cottin
Lyon, France

L.M. Fabbri
Modena, Italy

R. Farré
Barcelona, Spain

U. Frey
Basel, Switzerland

J. Gerritsen
Groningen, the Netherlands

P. Hiemstra
Leiden, the Netherlands

M.M. Hoepfer
Hanover, Germany

M. Humbert
Clamart, France

S. Kawut
Philadelphia, USA

P. Lévy
Grenoble, France

G.B. Migliori
Tradate, Italy

J. Müller-Quernheim
Freiburg, Germany

R. Naeije
Brussels, Belgium

M.I. Polkey
London, UK

G. Raghu
Seattle, USA

M. Saetta
Padova, Italy

J-P. Sculier
Brussels, Belgium

F. Sériès
Quebec City, Canada

P.D. Sly
Brisbane, Australia

J.B. Soriano
Bunyola, Spain

A. Torres
Barcelona, Spain

P.E. Van Schil
Edegem, Belgium

T. Welte
Hanover, Germany

M.A. Woodhead
Manchester, UK

S.G. Zakynthinos
Athens, Greece

ADVISORS

P-Y. Brillet
Bobigny, France
Radiology

A. Kettaneh
Paris, France
Statistics

S. Suissa
Montreal, Canada
Methodology

INTERNATIONAL ADVISORY BOARD

M.G. Belvisi
London, UK

E. Berglund
Gothenburg, Sweden

C. Brambilla
Grenoble, France

P.M.A. Calverley
Liverpool, UK

E. Canalis
Barcelona, Spain

U. Costabel
Essen, Germany

M. Decramer
Leuven, Belgium

R. Djukanovic
Southampton, UK

O. Eickelberg
Munich, Germany

S. Ewig
Bochum, Germany

P.N. Le Souëf
Perth, Australia

C.E. Mapp
Ferrara, Italy

E. Michelakis
Edmonton, Canada

B. Nemery
Leuven, Belgium

P. Palange
Rome, Italy

K.F. Rabe
Kiel, Germany

R. Rodriguez-Roisin
Barcelona, Spain

A.M.W.J. Schols
Maastricht, the Netherlands

N. Siafakas
Heraklion, Greece

A.K. Simonds
London, UK

P.J. Sterk
Amsterdam, the Netherlands

N.S. Zhong
Guangzhou, China



VIENNA

ORGANISATION OF THE 22ND ERS ANNUAL CONGRESS

CONGRESS SECRETARIAT

Sylvia Hartl (Congress Chair)
I. Dep. Pulmonary & Critical Care
Otto Wagner Hospital
Sanatoriumstrasse 2
AT-1140 Vienna, Austria
Tel: +43 19106041635
Fax: +43 19196049866
sylvia.hartl@wienkav.at

Michael Studnicka (Congress Co-Chair)
Univ.Klinik f. Pneumologie
Mullner Hauptstrasse 48
Landeskrankenhaus
AT-5020 Salzburg, Austria
Tel: +43 662 4482 3300
Fax: +43 662 4482 3303
M.Studnicka@salk.at

Laurent Pierre Nicod (Scientific Committee Chair)
Service de Pneumologie
Centre Hospitalier Universitaire
Vaudois
Rue du Bugnon 46
CH-1011 Lausanne, Switzerland
Tel: +41 213141380
Fax: +41 213141384
laurent.nicod@chuv.ch

GENERAL ORGANISATION

ERS Headquarters
4, Ave Sainte-Luce
CH-1003 Lausanne, Switzerland
Tel: +41 21 213 01 01
Fax: +41 21 213 01 00
info@ersnet.org
www.ersnet.org

Executive Director

Archie Turnbull

For any queries on abstracts: scientific@ersnet.org

COMMITTEES

Vienna Congress Committee

S. Hartl, AT (Congress Chair)
M. Studnicka, AT (Congress Co-Chair)
K.F. Rabe, DE (President)
M. Gaga, GR (Secretary General)
G. Joos, BE (Treasurer)
J. Gea, ES (Congress Chair 2013)
J. Garcia Aymerich, ES (Congress Co-Chair 2013)
L.P. Nicod, CH (Scientific Committee Chair)
A. Simonds, UK (School Committee Chair)

Vienna Programme Committee

L.P. Nicod, CH (Scientific Committee Chair)
S. Hartl, AT (Congress Chair)
M. Studnicka, AT (Congress Co-Chair)
and Heads of Scientific Assemblies

ERS Executive Committee

K.F. Rabe, DE (President)
M. Decramer, BE (Past President)
F. Blasi, IT (President Elect)
P.J. Barnes, UK (Vice President)
M. Gaga, GR (Secretary General)
G. Joos, BE (Treasurer)
L.P. Nicod, CH (Scientific Committee Chair)
A. Simonds, UK (School Committee Chair)
W. Wedzicha, UK (Guidelines Director)
Y. Sibille, BE (Secretary for EU Affairs)
M. Fletcher, UK (ELF Chair)
and Heads of Scientific Assemblies

Observers on the Executive Committee

J-P. Sculier, BE (Secretary for EU Affairs-Elect)

Tobacco Control Committee

C. Gratziau, GR (Chair)

Environment Committee

J. Ayres, UK (Chair)

Heads of Scientific Assemblies

A. Bohler, CH
B.G. Cooper, UK
V. Cottin, FR
W. De Backer, BE
E. Eber, AT
T. Geiser, CH
I. Horvath, HU
C. Lange, DE
B. Lundback, SE
P. Pelosi, IT
J-P. Sculier, BE

EUROPEAN RESPIRATORY *journal*

AIMS & SCOPE

The European Respiratory Journal (ERJ), the official Journal of the European Respiratory Society, publishes, in the English language, clinical and experimental work dealing with all aspects of respiratory medicine. In addition to original material, the *ERJ* prints Editorials and Reviews, as well as Letters and Correspondence.

This Journal is abstracted/indexed in: Ad Referendum, ADONIS, Biological Abstracts/BIOSIS, Chemical Abstracts, Current Contents: Life Sciences, Current Contents: Clinical Medicine, Elsevier BIOBASE/Current Awareness in Biological Sciences, EMBASE/Excerpta Medica, Index Medicus/MEDLINE, Medical Documentation Service, Research Alert, Science Citation Index, SciSearch, SIIC Data Base and CABI Global Health.

SUBSCRIPTIONS

ERJ is published monthly by the European Respiratory Society (ERS). Twelve issues are published annually in two volumes of six issues each. The volumes for 2012 are Volumes 39 and 40.

Subscription rates for institutions (Volumes 39 & 40, 2012): £673.00 online only, £794.00 print and online; US\$1,278.00 online only, US\$1,508.00 print and online in North America. Subscription rates include air economy postage. Subscriptions are payable in advance.

Subscribers within the European Union must provide their VAT (Value Added Tax) number or add VAT to the subscription rate at the rate prevailing in their own country.

Subscriptions are managed on behalf of the ERS by:
Maney Publishing, Suite 1C, Joseph's Well, Hanover Walk, Leeds LS3 1AB, UK (fax: +44 (0)113 386 8178; E-mail: subscriptions@maney.co.uk) or: Maney Publishing North America, 875 Massachusetts Avenue, 7th Floor, Cambridge, MA 02139, USA (tel: (toll-free) +1 (0)866 297 5154; fax: +1 (0)617 354 6875; E-mail: maney@maneyusa.com). All orders, payments, and claims for missing issues should be sent to Maney Publishing or to any subscription agent.

ONLINE ACCESS

© 2012 ERS. Authorisation to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted for libraries and other users registered with the Copyright Clearance Center (CCC). Please go to www.copyright.com or phone USA (978) 750 8400. UK customers should go to www.cla.co.uk. All other rights, including microfilm, electronic and/or copying reserved.

European Respiratory Journal, 0903-1936, is published monthly by the European Respiratory Society, 442 Glossop Road, Sheffield, S10 2PX, UK. Airfreight and mailing in the USA by agent named Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Periodicals postage paid at Jamaica NY 11434. US Postmaster: send address changes to European Respiratory Journal, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA. Subscription records are maintained at European Respiratory Society, 442 Glossop Road, Sheffield, S10 2PX, UK. Air Business Ltd is acting as our mailing agent.

Typesetting by H. Charlesworth & Co. Ltd.
Printed in UK by Page Bros (Norwich) Ltd.

"The advertiser shall be liable for the content of any of its advertisements published according to its instructions. The advertiser shall indemnify and hold harmless the European Respiratory Society against and from any and all claims, damages, liabilities, costs and expenses whatsoever, including reasonable counsel fees, arising from the content of any of its advertisements."

ERJ online at www.ersnet.org or
www.erj.ersjournals.com

Annual Congress

VIENNA

September 1 – 5, 2012

— **2012** —



ERS

EUROPEAN
RESPIRATORY
SOCIETY

every breath counts

ABSTRACTS

P4207**Alterations of serum inflammatory biomarkers in the healthy and lung cancer patients before and post chemotherapy**

Dawei Yang¹, Xun Wang¹, Tao Zeng², Jie Hu¹, Yuanlin Song¹, Luonan Chen², Xiangdong Wang¹, Chunxue Bai¹. ¹Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital Fudan University, Shanghai, China; ²Key Laboratory of Systems Biology, SIBS-Novo Nordisk Translational Research Centre for PreDiabetes, Shanghai Institutes for Biological Sciences, Shanghai, China

Introduction: Only 20% of lung cancer patients could be early diagnosed with surgical treatment. Due to the high cost, it is not practical to apply CT scan and pathological biopsy for lung cancer as regular screening tools even in high-risk population. A simple but sensitive and specific assay used for lung cancer diagnosis and prognosis is warranted.

Methods: Serum samples from 55 subjects including healthy people and patients with NSCLC (30 with adenocarcinoma and 13 with squamous cell carcinoma) were collected to measure 40 inflammatory mediators by multiplexed cytokine immunoassays. All patients have completed follow up for up to two years. A series of systematical computational analysis was applied.

Results: The set of 17 cytokines (such as IL-9, CCL16, CXCL10, etc.) prefers to identify adenocarcinoma samples from pool of the population, while the set of 2 cytokines (MSPa and IL-29) prefers to recognize squamous cell carcinoma samples. The decision trees based on these two kinds of biomarkers can both achieve about 80% accuracy in leave-one-out cross-validation. Cytokines like CXCL5, CXCL10 and CCL16 were also found to play important roles in cancer survival. The co-expressed protein interaction network (CEPIN) of cytokines related to adenocarcinoma show dynamic convergent behavior during chemotherapy.

Conclusions: This pattern of inflammatory mediators might be useful for cancer diagnosis, prognosis and evaluation of chemotherapy effects. The results of clustering of five CEPINs supported the adopted chemotherapy is effective for NSCLC patients.

This study was supported by National Basic Research Program of China (973 Program) No. 2012CB933300.

P4208**Anti-tumorigenic effect of age-/diabetes-related advanced glycation end-products in lung carcinoma**

Babett Bartling¹, Hans-Stefan Hofmann^{1,2}, Antonia Sohst¹, Veronika Somoza³, Rolf-Edgar Silber¹, Andreas Simm¹. ¹Cardiothoracic Surgery, University Hospital, Halle (Saale), Germany; ²Thoracic Surgery, Hospital Barmherzige Brüder, Regensburg, Germany; ³Research Platform for Molecular Food Science, University of Vienna, Austria

Background: Clinicopathological studies indicated that lung carcinoma progression is impaired by advanced age and diabetes, which are either characterized by accumulation of advanced glycation end-products (AGEs). AGEs result from the non-enzymatic reaction of sugars with proteins in the body and in foods. Therefore, our study aimed at the effect of AGEs on the non-small cell lung carcinoma (NSCLC) progression.

Methods: AGEs were quantified by detecting the AGE fluorescence in plasma samples of NSCLC patients prior to surgery. Experimentally, the tumor effect of circulating AGEs was studied by using NSCLC spheroids and plasma samples increasingly modified with AGEs, and NSCLC-bearing mice of whom elevated AGE level were induced by AGE-enriched food.

Results: High plasma AGE levels were characterized by a later reoccurrence of the tumor after curative surgery and a higher long-term survival rate compared to patients with low levels (25% vs. 47% 5-year-survival, $P = 0.011$). In this regard, *in vitro* studies showed a lower spheroid growth of NSCLC cells in the presence of AGE-modified plasma than non-modified plasma. By *in vitro* application of plasma samples from NSCLC patients or mice with different AGE levels, we also found an inverse correlation between the NSCLC spheroid growth and the plasma AGE level. Moreover, the *in vivo* tumorigenicity assay demonstrated that mice with higher levels of circulating AGEs developed smaller tumors than mice with normal AGE levels.

Conclusion: The plasma AGE level has prognostic relevance for NSCLC patients, in which the tumor growth-inhibiting effect of circulating AGEs might play a critical role.

P4209**Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer**

Marina Petrovic¹, Ivan Cekerevac¹, Gordana Kostic², Violeta Iric Cupic², Goran Davidovic², Zorica Lazic¹, Vojislav Cupurdija¹, Ljiljana Novkovic¹. ¹Pulmonary Department, Clinical Center, Kragujevac, Serbia; ²Clinical for Cardiology, Clinical Center, Kragujevac, Serbia

Introduction: Previous studies that were based primarily on small numbers of patients suggested that certain circulating proinflammatory cytokines may be associated with lung cancer; however, large independent studies are lacking.

Methods: Associations between serum interleukin 6 (IL-6) and interleukin 8 (IL-8) levels and lung cancer were analyzed among 123 case patients. Associations between biomarkers and lung cancer were estimated using logistic regression models adjusted for smoking, stage, histology, age, and sex. The 10-year standardized

absolute risks of lung cancer were estimated using a weighted Cox regression model.

Results: Serum IL-6 and IL-8 levels in the highest quartile were associated with lung cancer (IL-6, odds ratio [OR] = 2.89, 95% confidence interval [CI] = 1.28 to 6.23; IL-8, OR = 2.46, 95% CI = 1.02 to 4.12) and with lung cancer risk (IL-6, OR = 1.93, 95% CI = 0.87 to 2.36; IL-8, OR = 1.62, 95% CI = 1.56 to 2.48), compared with the lowest quartile. Increased IL-6 levels were only associated with lung cancer diagnosed within 2 years of blood collection, whereas increased IL-8 levels were associated with lung cancer diagnosed more than 2 years after blood collection (OR = 2.03, 95% CI = 1.05 to 2.73). The 10-year standardized absolute risks of lung cancer were highest among current smokers with high IL-8 and CRP levels (absolute risk = 7.46%, 95% CI = 4.52% to 10.25%).

Conclusions: Although increased levels of both serum IL-6 and IL-8 are associated with lung cancer, only IL-8 levels are associated with lung cancer risk several years before diagnosis.

P4210**Clinical significance of serum osteopontin levels in lung cancer**

Aikaterini Kazakou, Theodora Kerenidi, Martha Lada, Irini Tsilioni, Eleftherios Dalaveris, Konstantinos Gourgoulanis. Respiratory Medicine, University Hospital, Larissa, Greece

Background: Osteopontin (OPN) is a multifunctional glycoprotein associated with lung cancer (LC) via several pathways including tumour angiogenesis.

Aims and objectives: The aim of our study was to investigate possible associations between serum levels of OPN in patients with LC and clinicopathological variables, VEGF and MMP-9 levels and overall survival.

Methods: We enrolled 51 patients (mean age 66±8.8 years) with primary LC and 30 healthy control subjects. 43 patients were ever smokers and 8 non-smokers, 12 patients had SCLC and 39 NSCLC (18 squamous, 16 adenocarcinoma and 5 NSCLC-NOS) with stage I-II/4, III/18, IV/29. Serum levels of OPN, VEGF and MMP-9 were measured by ELISA.

Results: Patients with LC had statistically significantly higher serum OPN levels than controls (45.9[10.5-266.8] vs 16[6.8-29.8] ng/ml, $p < 0.0001$). ROC analysis showed that for OPN levels >23.8 ng/ml, sensitivity for detection of LC was 80.4% and specificity was 86.7%. OPN levels were also found higher in smokers ($p = 0.019$) and in older patients ($p = 0.026$). Moreover, patients with squamous LC had statistically significantly higher OPN levels compared to patients with adenocarcinoma. Additionally, patients with serum OPN levels lower than median value (<45.9 ng/ml) had significantly better overall survival than those with higher levels (524 days vs. 306 days, $p = 0.01$) and a 1-year survival rate of 80% vs. 37%. Finally, OPN levels were positively associated with VEGF levels ($r = 0.44$, $p = 0.001$).

Conclusions: OPN levels were increased in patients with LC, and higher levels were correlated with worse survival, therefore suggesting a possible diagnostic and prognostic value of OPN in patients with LC.

P4211**Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)**

Engin Aynaci¹, Ender Coskunpinar², Ayse Eren², Onur Kum¹, Yasemin Müsteri Öltülü², Nergiz Akkaya², Akif Turan³, Aysun Aynaci¹, İlhan Yaylim², Pinar Yıldız¹. ¹Pulmonology, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey; ²Department of Molecular Medicine, Istanbul University Institute of Experimental Medicine, Istanbul, Turkey

Introduction and aim: Survivin gene is one of the first reported inhibitors of apoptosis proteins (IAPs), which is an important family of proteins that regulate apoptosis. A common polymorphism at the survivin gene promoter (-31 G/C) has been shown to influence survivin expression and the risk for cancer development. Purpose of this study reports, relation between Turkish population who have survivin polymorphism and NSCLC also; its relevant with diseases's development and prognosis.

Methods: 146 NSCLC cases and 98 healthy control cases who were diagnosed at Yedikule Chest Diseases and Chest Surgery, Training and Research Hospital third clinic were included in this study. Pulmonary function test and routine biochemical analysis were done for all voluntaries. PCR-RFLP technique was used for genotyping.

Result: Genotype distribution of Survivin gene's -31G/C region were detected (n=146) %77.4 GG (n=113), %18.5 GC (n=27), %4.1 CC (n=6); at patient group and (n=98) % 6.1 GG (n=56), %47.5 GC (n=34), % 46.4 CC (n=8) (* $p = 0.003$), at control group; -644T/C region were detected (n=146) %40.4 TT (n=59), %48.6 TC (n=71), %11.0 CC (n=16); at patient group and (n=98) % 55.1 TT (n=54), %40.8 TC (n=40), % 4.1 CC (n=4) (* $p = 0.031$), at control group; -625G/C region were detected (n=146) %49.3 GG (n=72), %39.1 GC (n=57), %11.6 CC (n=17); at patient group and (n=98) % 57.1 GG (n=56), %32.7 GC (n=32), % 10.2 CC (n=10) ($p = 0.484$) at control group.

Conclusion: These results show that Survivin gene -31 G/C polymorphism causes predisposition to lung cancer development in Turkish population.